Development and characterization of glimepiride nanocrystal formulation and evaluation of its pharmacokinetic in rats

Drug Delivery

Volumn 20, Issue 1, 2013, Pages 25-33

  Du, Bin ^a,b   Shen, Guopeng ^c   Wang, Dandan ^d   Pang, Li ^d   Chen, Zheng ^d   Liu, Zhongying ^a  

^a JILIN UNIVERSITY   (China)

^b DAQING OILFIELD CO LTD   (China)

^c Zhengzhou University 100 Science Road   (China)

^d ZHENGZHOU UNIVERSITY   (China)

Author keywords

Dissolution rate; Glimepiride; Nanocrystal; Pharmacokinetic; Stability

Indexed keywords

CRYOPROTECTIVE AGENT; GLIMEPIRIDE; MACROGOL 6000; NANOCRYSTAL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; FREEZE DRYING; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; SUSPENSION; ULTRASOUND; X RAY DIFFRACTION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; MALE; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY; SULFONYLUREA COMPOUNDS; X-RAY DIFFRACTION;

EID: 84872221329     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2012.742939     Document Type: Article

References (25)

1. Ambrusa R, Kocbek P, Kristl J. (2009). Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam. Int J Pharm 381:153-9.
2. Du B, Li XT, Zhao Y, et al. (2010). Preparation and characterization of freeze-dried 2-methoxyestradiol nanoparticle powders. Pharmazie 65:471-6.
3. Eerdenbrugh VB, Mooter VG, Augustijns P. (2008). Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 364:64-75.
4. Fakes MG, Blisse JV, Feng Q, Sridhar D. (2009). Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. Int J Pharm 370:167-74.
5. Ganta S, Paxton JW, Baguley BC, Garg S. (2009). Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm 367:179-86.
6. Geinsen K. (1988). Special pharmacology of the new sulfonylurea glimepiride. Drug Res 38:1120-30.
7. Jacobs C, Muller RH. (2002). Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 19:189-94.
8. Kaushal AM, Gupta P, Bansal AK. (2004). Amorphous drug delivery systems: molecular aspects, design, and performance. Crit Rev Ther Drug Carrier Syst 21:133-93.
9. Keck CM, Mu?ller RH. (2006). Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 62:3-16.
10. Kesisoglou F. (2007). Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv. Drug Dev Rev 59:631-44.
11. Kipp J. (2004). The role of solid nanoparticle technology in the parenteral delivery of poor water-soluble drugs. Int J Pharm 284:109-22.
12. Kouichi I, Masaki W, Youhei N, et al. (2005). Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diab Res Clin Prac 68:250-7.
13. Lipinski C. (2002). Poor aqueous solubility - an industry wide problem in drug discovery. Am Pharm Rev 5:82-5.
14. Massimo MB. (2003). Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Ther 25:799-816.
15. Mauludin R, Mu?ller RH, Kecket CM. (2009). Development of an oral rutin nanocrystal formulation. Int J Pharm 370:202-9.
16. Moschwitzer J, Achleitner G, Pomper H, Mu?ller RH. (2004). Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm 58:615-19.
17. Patravale VB, Kulkarni RM. (2004). Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 56:827-40.
18. Pu XH, Sun J, Wang Y, Wang YJ. (2009). Development of a chemically stable 10-hydroxycamptothecin nanosuspensions. Int J Pharm 379:167-73.
19. Quan P, Xia D, Piao HZ, et al. (2011). Nitrendipine nanocrystals: its preparation, characterization, and in vitro-in vivo evaluation. AAPS PharmSciTech 12:1136-43.
20. Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov 3:785-96.
21. Rosario P, Claudio B, Piera F, et al. (2002). Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 16:53-61.
22. Shelesh J, Swarnlata S. (2010). Type 2 diabetes mellitus - its global prevalence and therapeutic strategies. Diab Metab Syndr 4:48-56.
23. Xia D, Quan P, Piao H, et al. (2010). Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci 40:325-34.
24. Yang W, Keith P, Johnston KP, et al. (2010). Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur J Pharm Biopharm 75:33-41.
25. Zhang DR, Tan TW, Gao L, et al. (2007). Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev Ind Pharm 33:569-75.